WELCOME TO The Biotechnology REPORT
Cook General Biotechnology
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Cell and Gene Therapy
BioMarin Pharmaceutical Inc. | December 17, 2021
BioMarin Pharmaceutical Inc. and Skyline Therapeutics a gene and cell therapy company focused on developing novel treatments for unmet medical needs, announced a multi-year global strategic collaboration for the discovery, development and commercialization of Adeno-Associated Virus gene therapies to treat genetic cardiovascular diseases.
The partnership will leverage Skyline Therapeutics' integrated AAV gene therapy platform based on its proprietary vector engineer...
GenScript | November 10, 2020
GenScript USA Inc., the world's leading research reagent provider, announced today that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for the cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit. This is the first commercially available test to specifically detect neutralizing antibodies without the use of live virus. Neutralizing antibodies, a subset of antibodies that are specifically able to block the ability of the virus to enter a cel...
Vaxess Technologies | October 27, 2021
Vaxess Technologies, a biotechnology startup developing the MIMIXTM sustained-release intradermal microneedle patch, celebrated the grand opening of their 3,600 square feet pilot GMP (Good Manufacturing Practices) manufacturing facility on Monday. The facility, which is located in Woburn, MA at one of the Cummings Park properties, will feature a state-of-the-art cleanroom where manufacturing of vaccine patches for clinical trials will take place. Using the clinical-grade patches produced in the ...
Medical, Industry Outlook
PRNewswire | June 28, 2023
QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets, and Unlearn, a pioneering technology company innovating machine learning to revolutionize medical research, today announced they have entered into a collaboration to accelerate and optimize QurAlis' clinical program in ALS with Unlearn's advanced generative artificial ...
Cell and Gene Therapy, Industrial Impact
Industrial Impact, Industry Outlook
Cell and Gene Therapy, Medical
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE